Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

March 01, 2021

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

February 17, 2021

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

February 12, 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

January 29, 2021

BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.

January 04, 2021

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

December 23, 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

December 11, 2020

December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.

December 04, 2020

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

November 30, 2020

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

November 23, 2020

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

November 16, 2020

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

November 16, 2020

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

November 10, 2020

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

October 20, 2020

Allyson Ocean, ​MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.

October 19, 2020

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

October 15, 2020

Allyson Ocean, MD, discussed the importance of clinical trials and how they should not be viewed as a last resort for patients with metastatic pancreatic cancer.

October 13, 2020

Gagandeep Brar, MD, discusses how the treatment paradigm has expanded in hepatocellular carcinoma, continuing sequencing challenges, and ongoing trials that are expected to impact the landscape.

October 01, 2020

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

October 01, 2020

In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.

September 30, 2020

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in ​locally advanced or metastatic esophageal carcinoma.